Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?

Jasmin V Waterhouse; James H Hull; Mark Linch

doi:10.1016/j.eururo.2020.04.027

Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?

Eur Urol. 2020 Jul;78(1):9-10. doi: 10.1016/j.eururo.2020.04.027. Epub 2020 Apr 21.

Authors

Jasmin V Waterhouse¹, James H Hull², Mark Linch³

Affiliations

¹ Department of Oncology, University College London Cancer Institute, London, UK.
² Department of Respiratory Medicine, Royal Brompton Hospital, Imperial College, London, UK.
³ Department of Oncology, University College London Cancer Institute, London, UK. Electronic address: m.linch@ucl.ac.uk.

Abstract

The current World Health Organization guidance is not to start corticosteroids, but there is no robust evidence of risk in patients with cancer and coronavirus disease 2019. A risk-benefit analysis should be performed for each patient on the use of steroids in cancer care.

Publication types

Editorial

MeSH terms

Adrenal Cortex Hormones / therapeutic use*
Antineoplastic Agents, Hormonal / therapeutic use
Antineoplastic Agents, Immunological / adverse effects
Betacoronavirus
COVID-19
Capillary Leak Syndrome / chemically induced
Capillary Leak Syndrome / drug therapy
Capillary Leak Syndrome / prevention & control
Coronavirus Infections / epidemiology*
Female
Humans
Inflammation / chemically induced
Inflammation / drug therapy
Kidney Neoplasms / drug therapy
Male
Pandemics
Pneumonia, Viral / epidemiology*
Practice Guidelines as Topic*
Prostatic Neoplasms / drug therapy
Risk Assessment
Risk Factors
SARS-CoV-2
Urinary Bladder Neoplasms / drug therapy
Urologic Neoplasms / drug therapy*

Substances

Adrenal Cortex Hormones
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Immunological